Literature DB >> 26227486

Met Signaling Cascade Is Amplified by the Recruitment of Phosphorylated Met to Lipid Rafts via CD24 and Leads to Drug Resistance in Endometrial Cancer Cell Lines.

Yoshihiro Joshua Ono1, Akiko Tanabe2, Tomohito Tanaka2, Yoshimichi Tanaka2, Masami Hayashi2, Yoshito Terai2, Masahide Ohmichi2.   

Abstract

Endometrial cancer is the most prevalent gynecologic cancer in the Western world, and the number of advanced chemotherapy-resistant cancers is increasing with the absolute increase in patients. The development of resistance to chemotherapeutic drugs by cancer cells represents a major challenge in the clinical cure of advanced and metastatic cancers. CD24 has been reported to be a marker for a poor prognosis in several tumors, and we herein examined the functions of CD24 in human endometrioid adenocarcinoma cell lines and evaluated how it contributes to cancer drug resistance. We demonstrated that CD24 was responsible for the recruitment of phosphorylated Met to the lipid raft domain of the cell membrane, resulting in amplification of the Met signaling cascade, ultimately leading endometrial cancer cells to express higher levels of ATP-binding cassette (ABC) transporters. Our findings suggest that CD24-mediated amplification of the Met cascade may contribute to the drug resistance of endometrial cancer. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26227486     DOI: 10.1158/1535-7163.MCT-15-0187

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  8 in total

1.  CD24 promoted cancer cell angiogenesis via Hsp90-mediated STAT3/VEGF signaling pathway in colorectal cancer.

Authors:  Xinying Wang; Yu Zhang; Yingying Zhao; Yanling Liang; Cheng Xiang; Huanyu Zhou; Hui Zhang; Qiang Zhang; Haitao Qing; Bo Jiang; Huabao Xiong; Liang Peng
Journal:  Oncotarget       Date:  2016-08-23

2.  The Chemokine Receptor CXCR4 and c-MET Cooperatively Promote Epithelial-Mesenchymal Transition in Gastric Cancer Cells.

Authors:  Yu Cheng; Yongxi Song; Jinglei Qu; Xiaofang Che; Na Song; Yibo Fan; Ti Wen; Ling Xu; Jing Gong; Xiaoxun Wang; Chenlu Zhang; Xiujuan Qu; Yunpeng Liu
Journal:  Transl Oncol       Date:  2018-02-27       Impact factor: 4.243

3.  Foretinib (GSK1363089) induces p53-dependent apoptosis in endometrial cancer.

Authors:  Yuhei Kogata; Tomohito Tanaka; Yoshihiro J Ono; Masami Hayashi; Yoshito Terai; Masahide Ohmichi
Journal:  Oncotarget       Date:  2018-04-27

4.  CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma.

Authors:  Shuai Lu; Yao Yao; Guolong Xu; Chao Zhou; Yuan Zhang; Jie Sun; Runqiu Jiang; Qing Shao; Yun Chen
Journal:  Cell Death Dis       Date:  2018-05-29       Impact factor: 8.469

Review 5.  Cholesterol and Sphingolipid Enriched Lipid Rafts as Therapeutic Targets in Cancer.

Authors:  Michela Codini; Mercedes Garcia-Gil; Elisabetta Albi
Journal:  Int J Mol Sci       Date:  2021-01-13       Impact factor: 5.923

Review 6.  The lipid rafts in cancer stem cell: a target to eradicate cancer.

Authors:  Shuo Zhang; Neng Zhu; Hong Fang Li; Jia Gu; Chan Juan Zhang; Duan Fang Liao; Li Qin
Journal:  Stem Cell Res Ther       Date:  2022-08-30       Impact factor: 8.079

7.  CD24 blunts the sensitivity of retinoblastoma to vincristine by modulating autophagy.

Authors:  Jie Sun; Dongju Feng; Huiyu Xi; Jiajing Luo; Zewei Zhou; Qinghuai Liu; Yun Chen; Qing Shao
Journal:  Mol Oncol       Date:  2020-06-13       Impact factor: 6.603

8.  CD24 Contributes to Treatment Effect in ABC-DLBCL Patients with R-CHOP Resistance.

Authors:  Li-Yan Qiao; Han-Bing Li; Yue Zhang; Di Shen; Peng Liu; Yi-Qun Che
Journal:  Pharmgenomics Pers Med       Date:  2021-05-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.